Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Weighted Avg Shares (Diluted) · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares (diluted) grows 3.8% year over year

Q4 FY2025 weighted avg shares (diluted) of 43.89M shares rose 3.8% year over year. Over 3 fiscal years it compounded at -32.7% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
43.89M— QoQ
Last fiscal yearDec 2025
43.89M+3.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.8%——
1 year+3.8%——
3-year CAGR-32.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
43.89M USD
Year-over-year change
+3.8%
4-year CAGR
-18.6%

Weighted Avg Shares (Diluted) vs competitors

How NNNN compares with its peers on the latest reported figures

  • NNNN's FY2025 weighted avg shares (diluted) of 43.89M shares is the 8th highest of the 11 companies compared; the peer median is 73.1M shares.
  • Its year-over-year change of +3.8% is the 4th highest of 10, against a peer median of +1.4%.
  • Over three fiscal years its annual growth of -32.7% compares with a peer median of +3.5%.
NNNN Competitors Peer median
Weighted Avg Shares (Diluted) for NNNN and competitors
Company Period LTM YoY 3-year CAGR
SNDLSNDL Inc.LTM Mar 2026261.05M -0.7%+3.9%
GOSSGossamer Bio, Inc.LTM Mar 2026229M -0.3%+39.3%
TALKTalkspace, Inc.LTM Mar 2026172.34M -1.2%+3.5%
CYHCommunity Health Systems, Inc.LTM Mar 2026135M +2.0%+1.3%
CMPSCOMPASS Pathways plcLTM Mar 202693.99M +27.7%+30.1%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
AVNSAvanos Medical, Inc.LTM Mar 202646.5M +0.2%-0.6%
NNNNAnbio Biotechnology Class A Ordinary SharesFY202543.89M +3.8%-32.7%
ANGOAngioDynamics, Inc.LTM Feb 202641.29M +1.4%+1.7%
CLPTClearPoint Neuro, Inc.LTM Mar 202628.64M +4.3%+5.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.96M +6.3%+3.0%
Peer median (excluding NNNN) 73.1M+1.4%+3.5%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.43M23.54M6.71M8.19M9.76M
Cost of Revenue1.89M10.98M3.35M2.3M1.25M
Gross Profit2.54M12.56M3.36M5.89M8.51M
Gross Margin57.4%53.4%50.1%71.9%87.2%
Research & Development0200K134.7K454.23K227.19K
Selling, General & Admin86.1K2.17M1.27M3.44M1.78M
Operating Expenses86.1K2.37M1.4M3.89M2M
Depreciation & Amortization06.25K13.04K00
EBITDA2.54M10.03M2.27M2.57M6.51M
EBITDA Margin57.3%42.6%33.8%31.4%66.7%
Operating Income2.46M10.2M1.96M2M6.51M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Interest Income042.25K165.34K337.51K160.28K
Interest Expense08K000
Other Income / Expenses79.94K(184.41K)292.78K377.48K717.46K
Income Before Tax2.54M10.01M2.25M2.37M7.23M
Pre-Tax Margin57.3%42.5%33.6%29.0%74.1%
Income Tax Expense00000
Net Income2.54M10.01M2.25M2.37M7.23M
Net Margin57.3%42.5%33.6%29.0%74.1%
EPS (Basic)0.030.070.020.060.16
EPS (Diluted)0.030.070.010.060.16
Weighted Avg Shares100M143.89M143.89M42.29M43.89M
Weighted Avg Shares (Diluted)100M143.89M187.78M42.29M43.89M

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.